HER2-(ultra)low expressing breast cancer

Clinical trials for HER2-(ultra)low expressing breast cancer explained in plain language.

Never miss a new study

Get alerted when new HER2-(ultra)low expressing breast cancer trials appear

Sign up with your email to follow new studies for HER2-(ultra)low expressing breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Trials to join now! 1

New study tracks how a targeted drug stacks up against chemo for Hard-to-Treat breast cancer

Disease control Recruiting now

This study follows over 1,100 adults with HER2-low breast cancer that cannot be removed by surgery or has spread. Researchers will compare how long patients stay on trastuzumab deruxtecan (a targeted drug) versus standard chemotherapy before needing a new treatment. The goal is t…

Matched conditions: HER2-(ULTRA)LOW EXPRESSING BREAST CANCER

Sponsor: Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company • Aim: Disease control

Last updated Aug 21, 2026 00:00 UTC

HER2-(ultra)low expressing breast cancer

Get alerted when new HER2-(ultra)low expressing breast cancer trials appear

New study tracks how a targeted drug stacks up against chemo for Hard-to-Treat breast cancer